Literature DB >> 17346995

Changes in composition and activities of 26S proteasomes under the action of doxorubicin--apoptosis inductor of erythroleukemic K562 cells.

Anna S Tsimokha1, Alexey G Mittenberg, Valentina A Kulichkova, Irina V Kozhukharova, Larisa N Gause, Irina M Konstantinova.   

Abstract

Changes in the subunit composition, phosphorylation of the subunits, and regulation of the activities of 26S proteasomes in proliferating cells undergoing programmed cell death have not been studied so far. Moreover, there are no reports on phosphorylation of proteasome subunits both in normal and in neoplastic cells during apoptosis. The data of the present study show for the first time that apoptosis inductor doxorubicin regulates subunit composition, enzymatic activities, and phosphorylation state of 26S proteasomes in neoplastic (proerythroleukemic K562) cells or, in other words, induces reprogramming of proteasome population. Furthermore, the phosphorylation state of proteasomes is found to be the mechanism controlling specificity of proteasomal proteolytic and endoribonuclease activities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17346995     DOI: 10.1016/j.cellbi.2007.01.018

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  9 in total

1.  Exogenous 26S proteasomes can enter living cells to influence gene expression in the recipient cells.

Authors:  V A Kulichkova; Y Y Vatazhok; A S Tsimokha; I V Kozhukharova; Y B Ermolaeva; I N Evteeva; A G Mittenberg; L N Gause; I M Konstantinova
Journal:  Dokl Biol Sci       Date:  2008 Nov-Dec

2.  Simultaneous EGFP and tag labeling of the β7 subunit for live imaging and affinity purification of functional human proteasomes.

Authors:  Valentina A Kulichkova; Tatiana O Artamonova; Julia J Zaykova; Julia B Ermolaeva; Mikhail A Khodorkovskii; Nikolai A Barlev; Alexey N Tomilin; Anna S Tsimokha
Journal:  Mol Biotechnol       Date:  2015-01       Impact factor: 2.695

Review 3.  The role of the proteasome in heart disease.

Authors:  Yi-Fan Li; Xuejun Wang
Journal:  Biochim Biophys Acta       Date:  2010-09-15

Review 4.  Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.

Authors:  Mark J Ranek; Xuejun Wang
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

5.  A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.

Authors:  Jinbao Liu; Hanqiao Zheng; Mingxin Tang; Youn-Chul Ryu; Xuejun Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-31       Impact factor: 4.733

6.  Proteomic analysis of affinity-purified extracellular proteasomes reveals exclusively 20S complexes.

Authors:  Valentina A Kulichkova; Tatiana O Artamonova; Olga G Lyublinskaya; Mikhail A Khodorkovskii; Alexey N Tomilin; Anna S Tsimokha
Journal:  Oncotarget       Date:  2017-11-01

7.  DNA damage modulates interactions between microRNAs and the 26S proteasome.

Authors:  Anna S Tsimokha; Valentina A Kulichkova; Elena V Karpova; Julia J Zaykova; Nikolai D Aksenov; Anastasia A Vasilishina; Andrei V Kropotov; Alexey Antonov; Nikolai A Barlev
Journal:  Oncotarget       Date:  2014-06-15

8.  Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity.

Authors:  Heba Samy Shoukry; Hania Ibrahim Ammar; Laila Ahmed Rashed; Maha Balegh Zikri; Ashraf Ali Shamaa; Sahar Gamal Abou Elfadl; Ejlal Abu-Al Rub; Sekaran Saravanan; Sanjiv Dhingra
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

9.  Post-Translational Modifications of Extracellular Proteasome.

Authors:  Anna S Tsimokha; Tatiana O Artamonova; Egor E Diakonov; Mikhail A Khodorkovskii; Alexey N Tomilin
Journal:  Molecules       Date:  2020-07-31       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.